Updated Safety Phase I Trial Of Anti-Lag-3 Alone And In Combination With Anti-Pd-1 In Patients With Recurrent Gbm.

Michael Lim,Xiaobu Ye,Anna F. Piotrowski,Arati Suvas Desai,Manmeet Singh Ahluwalia,Tobias Walbert,Joy D. Fisher,Serena Desideri,Louis B. Nabors,Patrick Y. Wen,Stuart A. Grossman

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 9|浏览32

暂无评分

摘要

2512Background: Preclinical GBM data targeting the checkpoint molecule Lag-3 have shown promising anti-tumor immune response with resultant improved survival when combined with anti-PD-1. Here we r...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要